TP53 and endometrial cancer: If available and feasible, it is recommended to do molecular classification testing (POLEmut, MMRd, non-specific molecular profile [NSMP], and p53 abnormal [p53abn]) in all patients with endometrial cancer to enable the meticulous stratification of patients into discrete prognostic risk groups and to furnish invaluable insights that possess the potential to exert influence over determinations concerning adjuvant and systemic therapeutic strategies (16).